UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001257
Receipt number R000001529
Scientific Title Hokkaido-Losartan/hydrochlorothiazide Investigation For End Point (H-LIFE study): Multi-center observational study on blood pressure control and cardio- and renoprotective effects of an ARB / diuretic combination in hypertensive patients in Hokkaido, Japan
Date of disclosure of the study information 2008/07/22
Last modified on 2014/01/22 20:35:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Hokkaido-Losartan/hydrochlorothiazide Investigation For End Point (H-LIFE study):
Multi-center observational study on blood pressure control and cardio- and renoprotective effects of an ARB / diuretic combination in hypertensive patients in Hokkaido, Japan

Acronym

H-LIFE study
:Hokkaido-Losartan/hydrochlorothiazide Investigation For End Point

Scientific Title

Hokkaido-Losartan/hydrochlorothiazide Investigation For End Point (H-LIFE study):
Multi-center observational study on blood pressure control and cardio- and renoprotective effects of an ARB / diuretic combination in hypertensive patients in Hokkaido, Japan

Scientific Title:Acronym

H-LIFE study
:Hokkaido-Losartan/hydrochlorothiazide Investigation For End Point

Region

Japan


Condition

Condition

Hypertension

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism
Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

1) To evaluate anti-hypertensive effect of losartan/HCTZ (Preminent), focusing on blood pressure control and cardio- and renoprotective effects.
2) To identify a group of patients with good response to losartan/HCTZ treatment by conducting a subgroup analysis of patients with cardiac- and renal complications.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1.Change in office blood-pressure
2.Change in BNP and NT-proBNP levels
3.Change in microalbuminuria, proteinuria and renal function

Key secondary outcomes

1.Frequency of cardiovascular events (fatal and non-fatal myocardial infarction, unstable angina, angina that required hospitalization, coronary revascularization, stroke etc)
2.Frequency of renal events (end-stage renal disease [ESRD], deterioration in renal function, etc)
3.Mortality
4.Rates of adverse events
5.Exploratory subgroup analysis


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Hypertensive patients for whom treatment with Preminent is planned since their blood pressure has not reached the target levels (SBP <140 mmHg and DBP <90mmHg; SBP <130 mmHg and DBP <80mmHg if patients are 65 years or younger, with chronic kidney disease or diabetes, or with a previous history of cardiovascular disease)
2)Men and women aged 20 years or older
3)Both outpatients and inpatients
4)Patients who fully understand study procedures and have given written informed consent to participate in the study

Key exclusion criteria

1)Patients with a history of hypersensitivity to ingredients of losartan/HCTZ
2)Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics
3)Pregnant (positive on a urine pregnancy test prior to the study) or breast feeding female patients, including one trying to conceive pregnancy during the planned study period
4)Patients with sever liver dysfunction
5)Patients with anuria or on dialysis
6)Patients with acute renal failure
7)Patients whose sodium and potassium levels in body fluids are clearly decreased

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroyuki Tsutsui

Organization

Hokkaido Clinical Hypertension Research Group
(Hokkaido University Graduate School of Medicine)

Division name

Cardiovascular Medicine

Zip code


Address

Kita 15, Nishi 7, Kita-ku, Sapporo, Japan

TEL

011-706-6973

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hisako Fujimoto

Organization

H-LIFE research secretariat

Division name

H-LIFE research secretariat

Zip code


Address

Yushima 1-chome Bldg., 1-6-3 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan

TEL

03-3814-9393

Homepage URL


Email

H-LIFE@n-place.co.jp


Sponsor or person

Institute

Hokkaido Clinical Hypertension Research Group

Institute

Department

Personal name



Funding Source

Organization

Japan Heart Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 07 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 02 Month 22 Day

Date of IRB


Anticipated trial start date

2008 Year 06 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry

2014 Year 03 Month 31 Day

Date trial data considered complete

2014 Year 05 Month 01 Day

Date analysis concluded

2014 Year 12 Month 01 Day


Other

Other related information

Prospective observational study


Management information

Registered date

2008 Year 07 Month 21 Day

Last modified on

2014 Year 01 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001529


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name